Meta-Analysis of the Efficacy and Safety of P2Y12 Inhibitor Monotherapy After Short Course of Dual-Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention

被引:2
|
作者
Elzanaty, Ahmed M. [1 ]
Nazir, Salik [2 ]
Awad, Mohammed T. [1 ]
Elsheikh, Eman [3 ]
Ahuja, Keerat Rai [4 ]
Donato, Anthony [5 ]
Eltahawy, Ehab A. [2 ]
机构
[1] Univ Toledo, Med Ctr, Dept Internal Med, 2801 W Bancroft St, Toledo, OH 43606 USA
[2] Univ Toledo, Med Ctr, Dept Cardiol, 2801 W Bancroft St, Toledo, OH 43606 USA
[3] Tama Univ Hosp, Dept Cardiol, Tanta, Egypt
[4] Cleveland Clin, Dept Cardiol, Heart & Vasc Inst, Cleveland, OH 44106 USA
[5] Tower Hlth Reading Hosp, W Reading, PA USA
关键词
Dual antiplatelet therapy; Short DAPT; P2Y(12) inhibitor monotherapy; DAPT duration; ELUTING STENT IMPLANTATION; MYOCARDIAL-INFARCTION; DOUBLE-BLIND; ASPIRIN; TRIAL; RISK; CLOPIDOGREL; TICAGRELOR; 6-MONTH; EVENTS;
D O I
10.1016/j.carrev.2020.05.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Guidelines recommend dual antiplatelet therapy (DAPT) following drug-eluting stent (DES) placement for >= 12 months in acute coronary syndrome or 6 months in stable coronary artery disease. However, with the advent of newer-generation stents, the optimal duration of DAPT to balance bleeding and thrombotic risks has been debated. Objectives: We aimed to perform a meta-analysis of randomized controlled trials (RCT) comparing P2Y(12) mono-therapy in short-duration group (SDG) vs. standard treatment group (STG) course of DAPT in patients undergoing PCI. Methods: Electronic databases were searched for RCTs of patients undergoing percutaneous coronary intervention (PCI) with DES placement who received short (<= 3 months) vs. standard DAPT course (>= 12 months) and were followed for >= 12-months. Rates ofmajor adverse cardiovascular events (a composite of cardiovascularmortality, non-fatal myocardial infarction, and non-fatal stroke) were the primary outcome. Study-specific odds ratios (OR) and corresponding 95% confidence intervals were calculated using random-effects model. Results: A total of 20,706 patients (10,344 in the SDG and 10,362 in the STG) were analysed from four studies. There was no significant difference observed forMACE (OR= 0.95, 95% CI: 0.81-1.08, P =.92, I-2= 0%) myocardial infarction or stent thrombosis. However, lower rates ofmajor bleedingwere noted in the SDG (1.20 vs. 1.80%; OR: 0.61; 95% CI: 0.37-0.99; P =.04; I-2 = 71%) albeit with increased heterogeneity. Conclusion: A short duration of DAPT followed by P2Y(12) inhibitormonotherapy was comparable to 12 months of DAPT with respect to MACE and thrombotic events, with lower rates of major bleeding events in select group of patients undergoing PCI. More data is needed to assess efficacy in patients with complex lesions and high risk ACS population including those with STEMI presentation. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:1500 / 1506
页数:7
相关论文
共 50 条
  • [31] P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention
    Zhou, Xuan
    Angiolillo, Dominick J.
    Ortega-Paz, Luis
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2022, 9 (10)
  • [32] Abbreviated Dual Antiplatelet Therapy Followed by P2Y12 Inhibitor Monotherapy versus 12 Months’ Dual Antiplatelet Therapy Post Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Ashish Kumar
    Mariam Shariff
    Rajkumar Doshi
    Igor Pedreira Vaz
    American Journal of Cardiovascular Drugs, 2020, 20 : 355 - 361
  • [33] Meta-Analysis of Brief Dual-Antiplatelet Therapy Duration After Percutaneous Coronary Intervention
    Krittanawong, Chayakrit
    Virk, Hafeez Ul Hassan
    Isath, Ameesh
    Wang, Zhen
    Naidu, Srihari S.
    Mehran, Roxana
    Birnbaum, Yochai
    Levine, Glenn N.
    Jneid, Hani
    AMERICAN JOURNAL OF CARDIOLOGY, 2022, 174 : 182 - 184
  • [34] P2Y12 Inhibitor Monotherapy After Short-Term Dual Antiplatelet Therapy in Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials
    Garg, A.
    Singh, S.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2024, 17 (04) : S10 - S10
  • [35] SAFETY OF P2Y12 INHIBITOR MONOTHERAPY AS COMPARED WITH A 12-MONTH COURSE OF DAPT AFTER PERCUTANEOUS CORONARY INTERVENTION
    Cerrud-Rodriguez, Roberto
    Assafin, Manaf
    Urrutia, Luis Cerna
    Weisz, Giora
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 28 - 28
  • [36] P2Y12 Inhibitor Monotherapy After Short-Term Dual Antiplatelet Therapy in Acute Coronary Syndrome
    Singh, Sahib
    Garg, Aakash
    Tantry, Udaya S.
    Bliden, Kevin
    Abbott, J. Dawn
    Gurbel, Paul A.
    AMERICAN JOURNAL OF CARDIOLOGY, 2024, 224 : 1 - 8
  • [37] P2y12 inhibitor monotherapy after 1-3 months dual antiplatelet therapy in patients with coronary artery disease and chronic kidney disease undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials
    Yu, Yanqiao
    Pan, Deng
    Bai, Ruina
    Luo, Jinwen
    Tan, Yu
    Duan, Wenhui
    Shi, Dazhuo
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [38] EFFICACY AND SAFETY OF TICAGRELOR MONOTHERAPY COMPARED WITH STANDARD DUAL ANTIPLATELET THERAPY IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION - A SYSTEMATIC REVIEW AND META-ANALYSIS
    Ullah, Irfan
    Mahfooz, Kamran
    Moeed, Abdul
    Zaidi, Syeda Farwa
    Waqar, Eisha
    Ahmed, Muhammad
    Virwani, Vikash
    Rehan, Syeda Tayyaba
    Hussain, Hassan Ul
    Irfan, Muhammad
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 1275 - 1275
  • [39] De-Escalation Dual Antiplatelet Therapy Prevail over Potent P2Y12 Inhibitor Monotherapy in Patients with Acute Coronary Syndrome Undergone Percutaneous Coronary Intervention: A Network Meta-Analysis
    Ding, Jing-Wen
    Chen, Yang
    Yu, Zuo-Zhong
    Zhao, Yuan-Bin
    Fan, Kun-Peng
    Yao, Xiong-Da
    Hu, Long-Long
    Liao, Yan-Hui
    Deng, Tian-Hua
    Xia, Yi
    Liao, Han-Hui
    Yang, Ren-Qiang
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2022, 23 (11)
  • [40] P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials
    Valgimigli, Marco
    Gragnano, Felice
    Branca, Mattia
    Franzone, Anna
    Baber, Usman
    Jang, Yangsoo
    Kimura, Takeshi
    Hahn, Joo-Yong
    Zhao, Qiang
    Windecker, Stephan
    Gibson, Charles M.
    Kim, Byeong-Keuk
    Watanabe, Hirotoshi
    Song, Young Bin
    Zhu, Yunpeng
    Vranckx, Pascal
    Mehta, Shamir
    Hong, Sung-Jin
    Ando, Kenji
    Gwon, Hyeon-Cheol
    Serruys, Patrick W.
    Dangas, George D.
    McFadden, Eugene P.
    Angiolillo, Dominick J.
    Heg, Dik
    Juni, Peter
    Mehran, Roxana
    BMJ-BRITISH MEDICAL JOURNAL, 2021, 373